SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549-1004
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): February 17, 2004
Ciphergen Biosystems, Inc.
(Exact name of Registrant as specified in its charter)
Delaware 000-31617 33-059-5156
(State or other jurisdiction of [Commission File (I.R.S. Employer
incorporation or organization) Number] Identification Number)
6611 Dumbarton Circle
Fremont, CA 94555
(Address of principal executive offices)
(510) 505-2100
(Registrant's telephone number, including area code)
Item 9. Regulation FD Disclosure (pursuant to "Item 12. Results of Operations
and Financial Condition").
A copy of the press release issued February 17, 2004 by the Registrant
announcing Financial Results for the Fourth Quarter and Fiscal Year 2003 is
filed under Items 9 and 12 of this Current Report on Form 8-K as Exhibit 99.1.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Ciphergen Biosystems, Inc.
(Registrant)
Date: February 17, 2004 By: /s/ William E. Rich
---------------------------------
William E. Rich
President and Chief Executive Officer
EXHIBIT INDEX
Exhibit
Number Description
----------- --------------------------------------------------------------
99.1 Press Release issued by Ciphergen Biosystems, Inc. on February
17, 2004